Table 2.
Clinical Outcomes at 12 months
| Dual Antiplatelet Therapy | Hazard Ratio (95% CI) | P Value | ||
|---|---|---|---|---|
| 3 mo (n=481) | 12 mo (n=491) | |||
| Target vessel failure | 8 (1.7) | 14 (2.9) | 0.58 (0.24–1.39) | 0.22 |
| Cardiac death | 2 (0.4) | 5 (1.1) | 0.41 (0.08–2.10) | 0.28 |
| Target vessel–related myocardial infarction | 1 (0.2) | 4 (0.8) | 0.26 (0.03–2.28) | 0.22 |
| Target vessel revascularization | 6 (1.4) | 8 (1.8) | 0.76 (0.26–2.19) | 0.61 |
| All‐cause death | 5 (1.1) | 6 (1.3) | 0.85 (0.26–2.78) | 0.79 |
| Any myocardial infarction | 2 (0.4) | 8 (1.7) | 0.25 (0.05–1.20) | 0.08 |
| Repeated revascularization | 11 (2.4) | 12 (2.6) | 0.93 (0.41–2.11) | 0.86 |
| Stent thrombosis | 0 | 0 | … | … |
| Stroke | 6 (1.3) | 3 (0.4) | 2.05 (0.51–8.18) | 0.31 |
| Bleeding BARC types 2–5 | 13 (2.8) | 19 (4.0) | 0.69 (0.34–1.40) | 0.30 |
| Major bleeding | 7 (1.5) | 5 (1.0) | 1.43 (0.46–4.51) | 0.54 |
| Major adverse cardiac and cerebrovascular events | 13 (2.8) | 14 (2.9) | 0.95 (0.45–2.02) | 0.89 |
| Net adverse clinical events | 16 (3.4) | 16 (3.3) | 1.02 (0.51–2.04) | 0.95 |
Data are n or n (%). The percentages are Kaplan–Meier estimates. BARC indicates Bleeding Academic Research Consortium.